Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Department of Health, Generalitat de Catalunya | OTHER_GOV |
| Hospital Vall d'Hebron | OTHER |
| Hospital Clinic of Barcelona | OTHER |
| Hospital Universitario 12 de Octubre |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.
A Target Trial Emulation study that tries to emulate the sequential specification of a target trial will be conducted measuring and controlling confounders when there is a common cause of vaccination and outcome event.
Participants will be provided with a Quick response (QR) code to access the RedCap study platform, which will guide them to the enrolment process. If the participant accepts and meets all the inclusion and none of the exclusion criteria, they will be directed to a baseline survey to self-collect sociodemographic data and information regarding risk factors, sexual behaviour, vaccination, and exposure to mpox.
Newly vaccinated participants will be matched 1:1 to unvaccinated controls. The matching will be performed based on the site of recruitment, and self-reported baseline sexual health and practices. Vaccinated and unvaccinated participants will be matched on variables associated with the probability of infection.
Follow-up will include regular surveys every month from the index date (i.e., enrolment date in the unvaccinated group, or vaccination date for the vaccinated group), to collect data on change on risk factors, sexual behaviour in the past month, vaccination status, and exposure to mpox. The participant will be asked to self-report if they develop symptoms suggestive of mpox, and the study platform will direct them to a specific mpox infection survey.
For each participant, follow-up will end at the earliest of the following events: mpox infection, voluntary withdraw, or the end of the study period. A health record review will be conducted to corroborate the diagnosis of new cases and to provide validity to the self-report.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Unvaccinated | Unvaccinated individuals who have risk factors for mpox infection and do not have a past history of mpox infection | ||
| Vaccinated | Vaccinated individuals with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) who have risk factors for monkeypox infection and do not have a past history of mpox infection. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mpox Vaccine | Drug | Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Polymerase chain reaction (PCR)-confirmed mpox infection | Mpox PCR positivity in participants with mpox infection symptoms | From 14 days after the index date to twelve months after the index date |
| Measure | Description | Time Frame |
|---|---|---|
| Polymerase chain reaction (PCR)-confirmed mpox infection | Mpox PCR positivity in participants with mpox infection symptoms | From immediately after the index date to twelve months after the index date |
| Duration of general symptoms |
Not provided
Inclusion Criteria:
Individuals aged 18 years or older.
Individuals with general risk factors for mpox infection, as currently defined by the local guidelines for vaccination. These risk factors include at least one of the following items:
Signature of informed consent.
Exclusion Criteria:
Male cis and Female trans
Not provided
Vaccinated and unvaccinated individuals who have risk factors for mpox infection and do not have a past history of mpox infection.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital ClÃnico San Borja Arriarán | Santiago | Santiago Metropolitan | 8360154 | Chile | ||
| Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34432976 | Background | Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernan MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475. Epub 2021 Aug 25. |
| Label | URL |
|---|---|
| Recommendations of experts in trial design to World Health Organization | View source |
Not provided
Upon request after publication
After Publication
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D045908 | Mpox, Monkeypox |
| ID | Term |
|---|---|
| D011213 | Poxviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D012900 | Smallpox Vaccine |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
| OTHER |
| Public Health Service of Madrid | OTHER |
| Madrid Salud | OTHER |
| Harvard School of Public Health (HSPH) | OTHER |
| London School of Hygiene and Tropical Medicine | OTHER |
| Germans Trias i Pujol Hospital | OTHER |
| BCN Checkpoint | INDUSTRY |
| Centro de Saluld Sandoval | UNKNOWN |
| Centro de Salud Montesa | UNKNOWN |
| Hospital Nacional Arzobispo Loayza | OTHER |
| Hospital Regional III Honorio Delgado | UNKNOWN |
| Hospital Regional Docente de Trujillo | UNKNOWN |
| Instituto Conmemorativo Gorgas de Estudios de la Salud | UNKNOWN |
| Ministerio de Salud de Panamá | UNKNOWN |
| Fundación Arriaran | UNKNOWN |
Not provided
Not provided
Not provided
Time from onset to resolution of general symptoms in participants with PCR-confirmed mpox infection (in days).
| From 14 days after the index date to twelve months after the index date |
| Severity of rash | Number of mpox lesions (lesions count) | From 14 days after the index date to twelve months after the index date |
| Duration of skin rash | Time from onset to resolution of skin rash in participants with PCR-confirmed | From 14 days after the index date to twelve months after the index date |
| Medical treatment | Requirement of medical treatment (yes/no) | From 14 days after the index date to twelve months after the index date |
| Hospitalization | Requirement of hospital admission (yes/no) | From 14 days after the index date to twelve months after the index date |
| Scarring | Residual scarring after mpox (yes/no) | From 14 days after the index date to twelve months after the index date |
| Safety and tolerability | Description of systemic and skin reactions | One month after vaccination |
| Panama City |
| Panama |
| Hospital Regional III Honorio Delgado | Arequipa | Peru |
| Hospital Nacional Arzobispo Loayza | Lima | 15082 | Peru |
| Hospital Regional Docente de Trujillo | Trujillo | 13011 | Peru |
| Germans Trias i Pujol Hospital | Badalona | Barcelona | 08916 | Spain |
| Spanish incidence estimation document for the calculation of the number of participants | View source |
| D018419 |
| Primate Diseases |
| D000820 | Animal Diseases |
| D012376 | Rodent Diseases |